Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
anakinra · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| placebo | PLACEBO_COMPARATOR | - |
| anakinra | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Anakinra (Kineret®) | DRUG | - |
| anakinra | DRUG | - |
| pegsunercept | DRUG | - |
| Placebo | DRUG | placebo |
Inclusion Criteria: - Subjects diagnosed with RA as determined by American College of Rheumatology (ACR) criteria with a disease duration of at least 24 weeks prior to enrollment - Active RA at screening as defined by EITHER: (1) At least 6 swollen joints (using a 66 joint count) and at least 6 tend...
Top 20 of 28 competitors
Anakinra is an investigational drug being studied for the treatment of rheumatoid arthritis and juvenile chronic arthritis. It is in Phase 2 clinical development for these indications. Anakinra is being developed by Amgen Inc. (NASDAQ: AMGN) and is a small molecule immunology therapy.
Anakinra is a small molecule immunology therapy being studied for rheumatoid arthritis and juvenile chronic arthritis. It is being evaluated in placebo-controlled clinical trials to assess its efficacy in reducing disease activity. The drug is administered to patients aged 2 years and older in clinical studies.
Anakinra is being developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol AMGN. The drug is currently in Phase 2 clinical trials for rheumatoid arthritis and juvenile chronic arthritis, with two completed studies involving a total of 86 participants.
Anakinra is in Phase 2 clinical development for rheumatoid arthritis and juvenile chronic arthritis. It has completed two Phase 2 trials, including one with 86 patients with juvenile chronic arthritis. Anakinra is not approved and remains an investigational drug under clinical evaluation.
Anakinra has been studied in two completed Phase 2 trials. NCT00037648 evaluated anakinra in 86 patients with juvenile chronic arthritis, while NCT00037700 assessed anakinra combined with pegsunercept in rheumatoid arthritis. Both trials were randomized, double-blind, and placebo-controlled.
Anakinra is also known as Kineret, as referenced in the clinical trial NCT00117091, which studied anakinra (Kineret) in combination with disease-modifying anti-rheumatic drugs in patients with active rheumatoid arthritis. This trial was Phase 3 and completed, though it is not part of the Phase 2 development program.